18/05/2026
台灣消融技術成績躍上國際版面:
"HistoSonics has established a strong clinical presence in Taiwan through National Taiwan University Hospital (NTUH), the company’s first installation site in the country. While awaiting TFDA approval, physicians at NTUH treated patients under research protocols and achieved the fastest rates of clinical adoption for histotripsy globally.
“Our early clinical experience with histotripsy has been very encouraging, not only for liver tumors but also for exploring future applications in other difficult-to-treat illnesses. Receiving TFDA approval is an important milestone for Taiwan and for Asia. We are excited to continue contributing to the clinical development and adoption of histotripsy in the region,” said Kai-Wen HUANG, Professor of surgical oncology at National Taiwan University Hospital. "
HistoSonics目前已透過台大醫院建立台灣首個臨床據點。在食藥署正式核准前一年內，台大醫院醫師團隊已於連床試驗下治療多位患者，並創下全球組織碎化消融技術臨床導入速度最快的紀錄。
負責該技術的台大醫院癌症微創中心教授黃凱文表示：「我們已經完成的碎化消融臨床經驗相當令人振奮，不僅成功應用於不可手術肝膽癌症，也正探索更多難治疾病的可能性。食藥署核准對台灣與亞洲都具有重要意義，我們期待持續推動這項技術在亞太地區的臨床發展與應用。」
HistoSonics Receives Landmark TFDA Approval in Taiwan, Accelerating Global Expansion
